Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,547.39
(
-0.68%
)
US TECH 100
23,307.60
(
-0.87%
)
Dow Jones
46,336.55
(
-0.20%
)
Brent Oil
102.10
(
3.36%
)
Bitcoin
69,386.05
(
-2.69%
)
News Focus
News Focus
Post# of 257292
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 512
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: oc631 post# 163946

Friday, 07/12/2013 12:33:54 PM

Friday, July 12, 2013 12:33:54 PM

Post# of 257292

Why wouldn't Russian regulators...



GILD is hoping that SOF+RBV will fare better in GT1b than the 50% that you quote.

PEG costs money, and that money does not go to GILD. This is a business decision that assumes that clinically the regimen will show enough efficacy to be competitive with IFN-based triples in a GT1b (easy to cure) dominant price-constrained market.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today